250 results about "Treated patient" patented technology

Introduced here are pressure-mitigation systems able to mitigate the pressure applied to a human body by the surface of an object (also referred to as a "structure") and assist a caretaker to move the human body. A controller device (or simply "controller") can be fluidically coupled to a pressure-mitigation device that includes a series of selectively inflatable chambers. When a pressure-mitigation device is placed between a human body and a surface, the controller can continuously, intelligently, and autonomously circulate fluid through the chambers of the pressure-mitigation device. Normally, the controller circulates air through the chambers of the pressure-mitigation device, though the controller could circulate another fluid, such as water or gel, through the chambers of the pressure-mitigation device. The controller may cause the chambers to be selectively inflated, deflated, or any combination thereof. As chambers selectively inflate, certain portions of the human body may be lifted above the surface, turned, or any combination thereof.

In various embodiments, provided herein are methods, devices and systems for transcatheter mitral valve replacement in a double-orifice mitral valve. These methods, devices and systems are used to treat patients with mitral valve disease, particularly those who have had failed edge-to-edge leaflet repair, or patients presently considered anatomically unsuitable for edge-to-edge leaflet repair alone.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Nicotine delivery devices and systems, particularly smoking cessation systems are provided by the present disclosure. Such devices and systems produce a nicotine-containing aerosol for inhalation that mimics smoking. The devices are capable of being adapted to control the amount of nicotine delivered to taper the amount of nicotine delivered to the user over time. Methods for treating patients to stop smoking are also disclosed. The devices, systems and methods can also be used to deliver other drugs disclosed herein, such as opioids (e.g., fentanyl).

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The present invention is in the field of ocular disease therapy. In particular, the invention relates to a composition comprising pimecrolimus for use in the topical treatment of moderate to severe blepharitis, in particular in a patient group comprising subjects with a clinical diagnosis of moderate to severe blepharitis, wherein the subjects to be treated have signs and symptoms of moderate to severe blepharitis characterised by swelling of the eyelid margin, ocular debris and ocular discomfort. In particular, the present invention relates to an ophthalmic composition that shows a high patient acceptance and a clinically meaningful improvement in the signs and symptoms of treated patients.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition with the effects of treating atrial fibrillation and improving anxiety, a medicine and a preparation method and application thereof. When the traditional Chinese medicine composition provided by the invention is combined with auricular point pressing beans to treat patients with atrial fibrillation and anxiety, clinical symptoms of atrial fibrillation and anxiety can be further improved, specifically, the score of traditional Chinese medicine syndromes is reduced, the effective rate of electrocardiograms and the clinical effective rate of anxiety are improved, the life quality of the patients is improved, and no obvious adverse reaction exists. Meanwhile, a traditional Chinese medicine oral administration and traditional Chinese medicine external treatment combined method is adopted, syndrome differentiation treatment can be carried out from the holism concept, the holographic therapy of external treatment of internal diseases can be utilized to the maximum extent, and a simple, convenient, safe and effective treatment thought is provided for early prevention, early diagnosis and early treatment of more diseases.

Provided herein are methods for determining a subtype of a small cell lung cancer in a patient based on the express status of ASCL1, NEUROD1, and POU2F3, which are expressed in a mutually exclusive fashion. The subtype of the cancer can be used to determine the sensitivity of the cancer to certain anti-cancer therapies. As such, also provided are methods of treating patients having small cell lung cancer based on the subtyping results.

The present invention relates to a topical formulation comprising at least one anticholinergic compound for use in treating patients suffering from severe hyperhidrosis, wherein administration of the formulation to the patient comprises: a) an initial phase with a topical administration of a predetermined amount of the formulation 5 to 7 times per week for a total time period of less than six months: followed by b) a maintenance phase with a topical administration of the same amount of the formulation 1 to less than 5 times per week.

1. Name of the designed product: Non-invasive respirator (HepoRes R2). 2. Use of the designed product: Medical equipment for treating patients with respiratory insufficiency requiring mechanical ventilation. 3. Design points of the designed product: in shape. 4. Picture or photo best indicating the design points: perspective view 1.

To provide a method of treating a patient with chronic heart failure using a medicament comprising neuregulin.SOLUTION: A companion diagnostic test is first performed on each patient prior to treatment, and the appropriate treatment is provided to each patient according to the companion diagnostic test results. If the test results are within a preferred therapeutic range for treatment, the patient is suitable for treatment of heart failure by administration of an effective amount of neuregulin.SELECTED DRAWING: None

The present disclosure provides liposomal particles comprising one or more active pharmaceutical ingredients (APIs) comprising at least one poorly water-soluble API located in an aqueous phase compartment inside the particle, pharmaceutical compositions thereof, and methods of preparing the same, and methods of preparing the same. And the use of the drug-loaded liposome and the pharmaceutical composition thereof for treating patients (including various types of cancer patients) to achieve a synergistic treatment effect. Also disclosed are therapeutic kits, dosage forms, and methods of preparing the drug-loaded liposomes and pharmaceutical compositions thereof.

The present disclosure provides methods for treating patients with myasthenia gravis, particularly patients who have been diagnosed of myasthenia gravis within 2 years.

The present invention provides tissue processing systems, apparatus, and methods. [Solution] Provided herein is a system for treating patient tissue. The system comprises an energy delivery console and at least one energy delivery device. The energy delivery console can deliver a first dose of energy and a second dose of energy. The energy delivery device comprises a first delivery element configured to deliver a first dose of energy to target tissue and a second delivery element configured to deliver a second dose of energy to target tissue. The first dose of energy may include the delivery of energy that reversibly alters the target tissue, and the second dose of energy may include the delivery of energy that irreversibly alters the target tissue. The first dose of energy is delivered to enhance the therapy provided by the second dose of energy.

The present invention relates inter alia to a combination of (i) a BCL-2 inhibitor and (ii) SEL24 / MEN1703 for use as a medicine, preferably for use in treating patients suffering from cancer. The present invention also relates to a kit of dosage forms comprising (i) a dosage form comprising a BCL-2 inhibitor and (ii) a dosage form comprising SEL24 / MEN1703, and to dosage forms comprising (i) a BCL-2 inhibitor and (ii) SEL24 / MEN1703.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The present invention solves the problem of providing a novel therapeutic agent for treating patients suffering from anti-NMDAR encephalitis. Patients suffering from anti-NMDAR encephalitis have pathogenic anti-human NR1 antibodies, which induce the internalization of NMDAR on the cell surface. As a result, the NMDAR function in the brains of such patients is weakened. The inventors of the present invention have found that the single-arm anti-human NR1 antibody according to the present invention competitively binds to NR1 with the pathogenic anti-human NR1 antibody and inhibits the internalization of NMDAR by the pathogenic anti-human NR1 antibody, thereby showing a therapeutic effect against anti-NMDAR encephalitis. Accordingly, the present invention provides a single-arm anti-human NR1 antibody, a polynucleotide encoding the antibody, an expression vector containing the polynucleotide, a host cell transformed by the expression vector, a method for producing the antibody, a pharmaceutical composition containing the antibody, the use of the antibody in the manufacture of the pharmaceutical composition, and a method for treating anti-NMDAR encephalitis using the antibody.

The invention relates to neurodegenerative disorders, and the diagnosis and / or prognosis of neurodegenerative disorders in a test subject using a lateral flow test, or the like. The invention also relates to detecting diagnostic and prognostic biomarkers in a range of various patient sample types for diagnosing and / or prognosing neurodegenerative disorders, such as Alzheimer's disease. The invention further provides biomarker detection methods, and apparatus and apparatuses for diagnosing and prognosing neurodegenerative disorders, and methods of treating patients diagnosed or prognosed with a neurodegenerative disorder. The invention also extends to detection of biomarkers and / or screening in pre-symptomatic subjects, for early diagnosis, to enable disease prevention or intervention.

An auricular stimulation device having surface electrodes biased towards each other, and offset from one another, is provided. The stimulation device can be positioned about the ear of a patient with each of the electrodes overlaying auricular ear tissue containing innervation supplied by an auricular branch of the vagus nerve. The electrodes transcutaneously stimulate the auricular branch. Also provided is a method of treating a patient using the auricular stimulation device. The stimulation device can be used for treating patients with conditions such as high blood pressure, depression, high blood glucose level, and tinnitus. Also provided is a diagnostic and therapeutic system having the auricular stimulation device, a smart device and a monitoring device. The smart device controls the auricular stimulation device based on biomarker information received from the monitoring device; and on information related to the patient, such as age, musculoskeletal stability, etc.; and / or on user input.

The invention provides stable ophthalmic formulations, a unit dose containing such formulations, medical kits, and methods for making and using such formulations and unit doses to treat patients suffering from a disorder mediated by an αv integrin, such as diabetic retinopathy.

Methods of treating patients with paralytic colon syndrome, wherein the method embodies devices that vibrate while supporting the patient. The method includes vibrating the patient in a supported position so as to urge an oscillating vertical displacement of approximately three to ten millimeters, wherein the vertical displacement is in a direction normal to a supporting surface of the supported position, and wherein the oscillation is at a frequency of at least five hertz and for a duration of at least ten minutes.

Systems, devices, user interfaces, and methods for managing patient conditions. A system for monitoring and / or managing a patient suffering from a brain condition may include a controller obtaining and / or storing data related to one or more monitored patient parameters contributing to the brain condition of the patient and displaying values of the one or more monitored patient parameters in trend lines over time on a user interface. The displayed trend lines may represent values of ventricular CSF volume, values of IVH volume, total ventricular volume in the brain, and / or values of other suitable parameters. The data related to the one or more monitored patient parameters may include images of the patient's brain and / or data derived from images of the patient's brain and / or suitable patient data.

The invention relates to a multifunctional nursing bed and a control method thereof.The multifunctional nursing bed comprises a bed head, a bed tail, an upper bed frame, a lower bed frame, a rotation driving device and a bottom bed frame, the bed frame is horizontally arranged at the top of the lower bed frame, the upper bed frame is rotationally arranged at the top of the lower bed frame with a vertical line as a rotating shaft, and the rotation driving device is arranged on the lower bed frame and drives the upper bed frame to rotate horizontally; the upper bed frame comprises a backrest frame, a waist frame, a leg lifting frame, a backrest overturning driving device and a leg lifting driving device, and the leg lifting driving device drives the leg lifting frame to overturn up and down. The rotary driving device is used for driving the upper bed frame to rotate horizontally, and the backrest overturning driving device is used for driving the backrest frame to overturn up and down, so that a patient can conveniently get in and out of the bed or change the rest posture of the patient. Besides, the leg lifting frame can lift the legs under the driving of the leg lifting driving device, so that a doctor or a nurse can treat the patient conveniently. Therefore, the upper bed frame can be changed into a backrest chair and can be flattened to realize the functions of sitting, sleeping and lifting legs.

The present disclosure relates to articles having an active pharmaceutical ingredient integrated into a thermoplastic polymer, as well as to methods of use and preparation of such articles. The articles are used, for example, for medical devices and for treating patients.

The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

A system and method for determining patient hospitalization risk and treating patients is disclosed. The system and method may include extracting patient data from one or more databases corresponding to a pool of patients having end stage renal disease; using a predictive model with the extracted patient data to generate, for each of the patients, a respective expected probability for hospitalization within a predetermined time period; identifying a subset of patients having respective expected probabilities that are higher than other patients in the pool of patients; identifying, for each patient, at least one factor from the patient data that increased the expected probability of hospitalization; and based on the identified factors, determining and executing clinical interventions to lower the probability of hospitalization within the subset of the pool of patients.

To provide a method for treating patients having HER2-positive metastatic or locally advanced breast cancer in first-line therapy.SOLUTION: A method comprising administering a therapeutically effective amount of an anti-HER2 maytansinoid conjugate to a patient having breast cancer who has received prior treatment with a taxane.SELECTED DRAWING: None